Lebwohl, M., B. Strober, T. Scharnitz, M. Linaberry, K. Hoyt, S. Banerjee, R. M. Kisa, and G. Martin. “Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: Evaluation of Creatine Phosphokinase Elevations in the Phase 3 POETYK PSO-1 and PSO-2 Trials”. SKIN The Journal of Cutaneous Medicine, vol. 7, no. 6, Nov. 2023, p. s244, doi:10.25251/skin.7.supp.244.